BindingDB logo
myBDB logout

891 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27958732 93 Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes asa7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship.EBI Bristol-Myers Squibb
27783977 12 Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.EBI Keimyung University
28105286 66 Discovery of a Potent, Selective, and Orally Available PI3Kd Inhibitor for the Treatment of Inflammatory Diseases.EBI Rhône-Poulenc Rorer
27955926 16 Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.EBI Shenyang Pharmaceutical University
27939174 84 Challenges in the development of an MEBI Vanderbilt University Medical Center
27517806 2 Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.EBI Tasly Pharmaceutical Group Co., Ltd.
28105282 95 Discovery of Chromane Propionic Acid Analogues as Selective Agonists of GPR120 withEBI Merck& Co.
27979595 73 Imidazopyridyl compounds as aldosterone synthase inhibitors.EBI Merck USA
27884697 65 3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.EBI CXS Corporation
27839686 65 Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.EBI Merck Research Laboratories
27836402 44 Design and synthesis of water soluble▀-aminosulfone analogues of SCH 900229 as┐-secretase inhibitors.EBI Merck Research Laboratories
27815121 132 Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.EBI Merck& Co.
27541271 247 Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.EBI Genentech Inc.
27933810 166 Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HTEBI National Institute of Diabetes and Digestive and Kidney Diseases
27658368 54 Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.EBI F. Hoffmann-La Roche Ltd
27606885 103 Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the NaEBI Sanofi-Aventis Deutschland GmbH
27575469 15 Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound.EBI Vanderbilt University Medical Center
27433829 35 Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-CeEBI Genomics Institute of the Novartis Research Foundation
27583770 82 Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two LockeEBI Bristol-Myers Squibb Research and Development
27579727 33 Discovery of 8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine (JNJ-46356479), a Selective and Orally Bioavailable mGlu2 Receptor Positive Allosteric Modulator (PAM).EBI Janssen Research& Development
27548392 76 Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.EBI Janssen Pharmaceutical Research& Development, LLC
27527804 109 Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).EBI Teva Branded Pharmaceutical Products R&D
27660692 70 Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-┐ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.EBI Infinity Pharmaceuticals, Inc.
27599745 106 Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.EBI Vitae Pharmaceuticals
27579577 91 Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers.EBI Actelion Pharmaceuticals Ltd.
27564135 499 1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.EBI Aptuit s.r.l.
27326332 66 Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.EBI Bristol-Myers Squibb Company
27145071 37 2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.EBI Palacky University in Olomouc
26914985 124 Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.EBI Boehringer Ingelheim RCV GmbH& Co KG
27096048 80 Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.EBI Peking Union Medical College and Chinese Academy of Medical Sciences
26962886 65 Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.EBI Universit£ di Perugia
26990539 79 Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR)▀ Agonist.EBI Vitae Pharmaceuticals, Inc.
27190604 26 Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.EBI Boehringer Ingelheim (Canada) Ltd.
27185330 60 Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.EBI Vanderbilt University Medical Center
27055065 92 Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.EBI The Institute of Cancer Research
27106708 130 The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.EBI Merck Research Laboratories
27105029 37 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.EBI Universit£ Lille Nord de France
27002486 15 Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.EBI University of Cambridge
26985323 5 Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.EBI Merck Research Laboratories
26985315 49 Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.EBI Xenon Pharmaceuticals, Inc.
26985314 23 Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain A▀ Reduction in Rodents.EBI Bristol-Myers Squibb Company
27131990 59 Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy.EBI Vanderbilt University Medical Center
27080185 46 Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.EBI Merck Research Laboratories
26924461 45 Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.EBI Bristol-Myers Squibb Research and Development
27020304 31 Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists.EBI Lilly Research Laboratories
27017115 77 Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.EBI Merck Research Laboratories
26988308 130 N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents.EBI Vanderbilt University Medical Center
26988302 104 Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs.EBI Vanderbilt University Medical Center
26985297 60 Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.EBI Roche Innovation Center Basel
27055941 19 Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1).EBI Bristol-Myers Squibb Research and Development
26951894 376 1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.EBI Aptuit s.r.l
26897089 39 Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.EBI Vitae Pharmaceuticals
26819660 82 SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR┐ Inhibitor.EBI Central Pharmaceutical Research Institute
26771665 41 Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1.EBI Karolinska Institutet
26751273 92 Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.EBI GlaxoSmithKline
26741947 24 The Rational Design of Selective Benzoxazepin Inhibitors of thea-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).EBI Genentech
26917221 69 Structure activity relationship studies on chemically non-reactive glycine sulfonamide inhibitors of diacylglycerol lipase.EBI Bristol-Myers Squibb Co.
26709102 142 Discovery of Vibegron: A Potent and Selective▀3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.EBI Merck Research Laboratories
26778256 145 Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.EBI Vanderbilt University Medical Center
26653735 81 Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI Pfizer Inc.
26764191 38 Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile.EBI Lilly Research Laboratories
26786693 153 Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.EBI Aptuit s.r.l
26652860 68 A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.EBI Korea Institute of Science and Technology (KIST)
26522950 60 Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).EBI Novartis Institutes for BioMedical Research
26509551 31 Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.EBI Pfizer Inc.
26475522 81 Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.EBI Vanderbilt University Medical Center
26363868 10 3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.EBI NorthShore University HealthSystem
26428869 7 Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M(1) and M(4) muscarinic acetylcholine receptors agonists.EBI Sumitomo Dainippon Pharma Co. Ltd.
26355532 18 Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).EBI Korea University of Science and Technology (UST)
26496070 96 Discovery of a Novel, Potent Spirocyclic Series of┐-Secretase Inhibitors.EBI Merck Research Laboratories
26426481 114 Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in SchizophrenicsEBI Vanderbilt University
25978966 65 Development of a novel class of potent and selective FIXa inhibitors.EBI Merck Research Laboratories
26403853 32 Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.EBI Roche Pharma Research and Early Development (pRED)
26313252 22 Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.EBI AstraZeneca
26288692 37 Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.EBI Bristol Myers-Squibb Research and Development
26335039 320 Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.EBI Vanderbilt University Medical Center
26299347 4 Optimization of a small molecule probe that restores e-cadherin expression.EBI Vanderbilt University Medical Center
26344593 5 Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.EBI NorthShore University HealthSystem
26191360 99 Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.EBI Merck Research Laboratories
26231163 50 Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.EBI Actelion Pharmaceuticals Ltd
26259804 23 Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.EBI Novartis Institutes for BioMedical Research
26134551 25 Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors.EBI Seoul National University
26291341 66 Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.EBI AstraZeneca
26225459 48 Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).EBI Heptares Therapeutics Ltd.
26191364 10 Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of Cancer.EBI Bristol-Myers Squibb Research
26191358 105 Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).EBI Euroscreen SA
26183084 53 Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.EBI Vanderbilt University Medical Center
26037322 100 3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1.EBI Uppsala University
26182238 1 Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime▀-Catenin Pathway Inhibitors.EBI University of Utah
26115573 67 Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.EBI Merck Research Laboratories
26105194 24 Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
26091726 41 Discovery and characterization of a potent and selective EP4 receptor antagonist.EBI Lilly Research Laboratories
26078010 28 Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain without CYP inhibition liability.EBI Astellas Pharma Inc.
26181715 73 Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.EBI Columbia University Medical Center
25286150 75 Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.EBI AstraZeneca
23033255 177 Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.EBI Tongji University
22328583 132 Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.EBI Pfizer Inc.
25655723 27 Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.EBI Teva Branded Pharmaceutical Products R&D, Inc.
25577041 7 Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.EBI Vertex Pharmaceuticals Inc
25082126 34 Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.EBI Chung-Ang University
25082125 12 Synthesis and biological evaluation of thienopyrimidine derivatives as GPR119 agonists.EBI Korea Research Institute of Chemical Technology
26039570 100 Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.EBI Vertex Pharmaceuticals, Inc.
26071371 26 Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain.EBI Astellas Pharma Inc.
26101566 14 Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.EBI AbbVie, Inc.
25953512 74 Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.EBI Eisai Co., Ltd.
26087021 94 Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.EBI TBA
26005524 147 Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.EBI Merck Research Laboratories
25992974 14 Synthesis and Biological Evaluation of Novel Olean-28,13▀-lactams as Potential Antiprostate Cancer Agents.EBI China Pharmaceutical University
25879485 60 Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.EBI Seragon Pharmaceuticals
25893048 25 Novel benzamide-based histamine h3 receptor antagonists: the identification of two candidates for clinical development.EBI Janssen Pharmaceutical Company
21289076 2 Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.EBI University of Helsinki
23118326 5 Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.EBI Onyx Pharmaceuticals
22496391 40 Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.EBI Bristol-Myers Squibb Research
22645092 15 Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.EBI Pfizer Inc.
22930276 25 Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.EBI Amgen, Inc
23132334 28 In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.EBI GlaxoSmithKline
22531045 2 In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties.EBI Amgen Inc.
22752007 1 Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.EBI Toyama Prefectural University
25941547 12 Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.EBI Roche Innovation Center Shanghai
25738882 210 Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).EBI Euroscreen SA
25827402 54 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.EBI Teva Global R&D.
25734520 104 Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.EBI Roche Innovation Center Shanghai
25711516 118 Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.EBI Saarland University and Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
25671290 106 Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).EBI Boehringer Ingelheim Pharmaceuticals
25838147 75 Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.EBI Actelion Pharmaceuticals Ltd
25723005 111 The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.EBI TBA
25680029 12 Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.EBI The Institute of Cancer Research
25603482 54 Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.EBI Array BioPharma Inc
25422861 78 In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.EBI National Institute of Diabetes and Digestive and Kidney Diseases
25801932 55 Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.EBI Vanderbilt University Medical Center
25782742 76 trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.EBI Novartis Pharma AG
25754490 44 trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.EBI Novartis Pharma AG
25701253 23 Synthesis and SAR studies of analogues of 4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063) as adenosine A2A receptor ligands with improved aqueous solubility.EBI H. Lundbeck A/S
25683622 86 Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).EBI Janssen Research and Development
25686852 191 Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARa/┐ agonists.EBI Bristol-Myers Squibb Research and Development (R&D)
25699143 26 Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists.EBI Pfizer Inc.
25597006 8 Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.EBI Vertex Pharmaceuticals Inc.
25577040 54 Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.EBI Merck Research Laboratories
25556090 99 Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.EBI Genentech Inc.
25415535 118 Inhibitors of c-Jun N-terminal kinases: an update.EBI Eberhard Karls Universit£t T£bingen
25089810 79 Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.EBI National Taiwan University
25088191 77 Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.EBI Arena Pharmaceuticals Inc.
25050172 32 Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.EBI AstraZeneca
25050169 52 Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11▀-Hydroxysteroid Dehydrogenase Type 1 (11▀-HSD-1).EBI Bristol-Myers Squibb
25050166 58 Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.EBI Novartis Institutes for BioMedical Research
25043312 104 Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.EBI University Health Network
25037916 185 Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.EBI Genentech
25036791 56 Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor.EBI National Taiwan University
24980053 153 Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.EBI Bristol-Myers Squibb Company
24974340 90 Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.EBI Korea University
24969015 118 Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.EBI Vanderbilt University Medical Center
24948565 20 Design and optimization of highly-selective fungal CYP51 inhibitors.EBI Viamet Pharmaceuticals Inc.
24939756 28 Strategies for the modulation of phase II metabolism in a series of PKCe inhibitors.EBI Vertex Pharmaceuticals
24867403 156 The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.EBI EntreMed Inc.
25589928 37 Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.EBI Novartis Institutes for Biomedical Research
25575658 83 Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.EBI Boehringer Ingelheim Pharmaceuticals
25556092 85 Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
25516794 71 (7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.EBI Arena Pharmaceuticals, Inc.
25516791 177 Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.EBI Boehringer Ingelheim Pharmaceuticals
25516790 37 Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.EBI Arena Pharmaceuticals, Inc.
25499880 51 Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.EBI RaQualia Pharma Inc
25456079 18 Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels.EBI Astellas Pharma Inc.
25455487 4 Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.EBI Institut Pasteur Korea
25454273 52 Anilinotriazoles as potent gamma secretase modulators.EBI Janssen Research& Development
25453808 101 Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.EBI Bristol-Myers Squibb Company
25441013 49 Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.EBI Vertex Pharmaceuticals Inc
25431977 100 Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles.EBI GlaxoSmithKline
25423411 28 Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).EBI Vanderbilt University School of Medicine
25409491 83 A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.EBI Zhejiang University
25393851 10 Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.EBI Boehringer Ingelheim (Canada) Ltd.
25369270 93 Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.EBI Galapagos NV
25330343 49 Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.EBI Translational Research Institute
25249180 146 The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.EBI GlaxoSmithKline R&D
25248679 85 Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.EBI Merck Research Laboratories
25221667 66 Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity.EBI Vanderbilt University
25221665 33 Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.EBI Janssen Pharmaceutica NV
25221656 116 Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-a-Oxyazetidine.EBI Korea University
25210858 96 Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.EBI Albany Molecular Research
25193232 32 Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.EBI Genentech Inc.
25179681 81 Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.EBI Chinese Academy of Sciences
25176194 69 The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.EBI Xenon Pharmaceuticals Inc.
25148100 9 Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).EBI Alla Chem LLC
24914612 36 Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).EBI Vanderbilt University Medical Center
24870926 50 Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.EBI Institut Pasteur Korea
24835202 68 Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.EBI AstraZeneca
24139169 175 Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.EBI Nerviano Medical Sciences
24914738 43 Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.EBI AstraZeneca
24900882 30 Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.EBI Merck Research Laboratories
24900877 107 Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.EBI Merck Research Laboratories
24900876 56 Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.EBI AstraZeneca
24900870 4 Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.EBI Second Military Medical University
24900867 2 Biarylmethoxy Nicotinamides As Novel and Specific Inhibitors of Mycobacterium tuberculosis.EBI Alkem Laboratories, Ltd.
24899257 71 Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.EBI Saarland University
24874895 42 Lead optimization of 1,4-azaindoles as antimycobacterial agents.EBI AstraZeneca
24874438 42 Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.EBI Chinese Academy of Sciences
24842618 56 The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.EBI AMRI
24794746 168 Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.EBI Aurigene Discovery Technologies Limited
24793360 29 Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.EBI Universit£ Lille Nord de France
24785301 83 Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.EBI AstraZeneca
24814197 63 Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines asa7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.EBI Critical Therapeutics, Inc.
24786585 200 Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-▀ type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.EBI Ewha Womans University
24779514 128 Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.EBI Gilead Sciences, Inc.
24758746 36 Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.EBI Janssen Research& Development
24755431 59 The discovery of diazepinone-based 5-HT3 receptor partial agonists.EBI AMRI
24755427 107 The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.EBI AstraZeneca
24712661 47 Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor▀ agonist in clinical trials for the treatment of dyslipidemia.EBI Madrigal Pharmaceuticals, Inc.
24689770 4 Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).EBI MRC Technology
24685542 67 Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.EBI Bristol-Myers Squibb Research and Development
24182233 57 Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.EBI Bristol-Myers Squibb
24630411 38 Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.EBI Merck Research Laboratories
24588963 21 Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.EBI Yuhan Research Institute
24520947 87 Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.EBI Hoffmann-La Roche Inc.
24512187 69 Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.EBI Pfizer Inc.
24666203 124 Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.EBI Genomics Institute of the Novartis Research Foundation
24508133 4 Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP(1) receptor antagonists for treatment of overactive bladder by core structure replacement.EBI Asahi Kasei Pharma Corporation
24450589 64 Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.EBI GlaxoSmithKline
24437735 16 Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective▀3 adrenergic receptor agonists for the treatment of overactive bladder.EBI Merck and Co.
24428186 10 Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione┐-secretase modulators.EBI Pfizer Inc.
24405419 96 Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).EBI Genentech
24397558 45 Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.EBI Bristol-Myers Squibb Research and Development
24359185 4 Discovery of a rapidly metabolized, long-acting▀(2) adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing.EBI GlaxoSmithKline Medicines Research Centre
23544424 4 Hepatitis C replication inhibitors that target the viral NS4B protein.EBI GlaxoSmithKline Research and Development
24568313 4 Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.EBI GlaxoSmithKline
24513042 22 Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.EBI Teva Pharmaceutical Global R&D
24266880 12 Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.EBI PTC Therapeutics, Inc.
24461352 51 Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.EBI Vanderbilt University Medical Center
24447850 122 Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.EBI Actelion Pharmaceuticals Ltd
24424134 76 Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.EBI Bristol-Myers Squibb
24412072 28 Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).EBI Gilead Sciences
24412066 5 Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.EBI Hoffmann-La Roche Inc.
24411125 36 Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.EBI Gilead Sciences
24486134 4 Substituted piperidines as HDM2 inhibitors.EBI Merck Research Laboratories
24261862 23 Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.EBI BioFocus
24360604 60 Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11▀-hydroxysteroid dehydrogenase type 1 (11▀-HSD1).EBI Bristol-Myers Squibb
24237195 46 High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.EBI University of Utah
24164599 9 Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).EBI Vanderbilt University
24332627 26 Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.EBI Shanghai Hengrui Pharmaceutical Co. Ltd
24252546 9 SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.EBI Asahi Kasei Pharma Corporation
24252545 12 Discovery of an irreversible HCV NS5B polymerase inhibitor.EBI Merck Research Laboratories
24157370 22 The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.EBI Chugai Pharmaceutical Co., Ltd
24157366 46 Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.EBI Merck Research Laboratories
24139584 17 Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.EBI Sanofi US
24120540 44 Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.EBI Merck Research Laboratories
24021582 52 Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.EBI Novartis Institutes for Biomedical Research
24093940 85 Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.EBI Hoffmann-La Roche Inc.
24090135 201 Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.EBI Sanofi
24044938 6 Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring.EBI Research Foundation Itsuu Laboratory
24044867 86 Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.EBI Califia Bio Inc.
24042009 89 Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.EBI Genentech Inc.
24035485 48 Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.EBI Merck Research Laboratories
24069953 6 Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.EBI Hoffmann-La Roche Inc.
24050755 10 Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).EBI Vanderbilt University
23973211 145 Fragment-based discovery of focal adhesion kinase inhibitors.EBI Merck KGaA
23905680 8 Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.EBI National Taiwan University
23352510 37 Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.EBI Roche Palo Alto
23855836 147 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.EBI Newcastle University
23820386 32 Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.EBI Novartis Institutes for Biomedical Research
23932792 74 Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.EBI Vanderbilt University Medical Center
23899614 60 Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).EBI Genentech Inc
23899349 69 Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.EBI AstraZeneca
23867602 122 Lead identification of novel and selective TYK2 inhibitors.EBI Genentech
23896611 16 Tetrazole-based deoxyamodiaquines: synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.EBI University of Cape Town
23890837 16 Design and synthesis of bicyclic heterocycles as potent┐-secretase modulators.EBI Janssen Research& Development
23845281 25 Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17▀-hydroxysteroid dehydrogenase inhibitor.EBI Astellas Pharma Inc.
23829549 145 The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.EBI EntreMed Inc.
23829483 32 Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.EBI University College London
23810497 51 Hydantoin based inhibitors of MMP13--discovery of AZD6605.EBI AstraZeneca
23810496 31 Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.EBI Korea Research Institute of Chemical Technology
23808489 11 2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.EBI Merck Research Laboratories
23806553 7 Discovery of triazines as potent, selective and orally active PDE4 inhibitors.EBI BioCrea GmbH
23769643 28 Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.EBI Sanofi US
23768906 5 Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.EBI Boehringer Ingelheim (Canada) Ltd
23632269 9 Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.EBI Bristol-Myers Squibb R&D
23668988 81 Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.EBI Genentech
23664879 73 Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.EBI GlaxoSmithKline
23324405 49 Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.EBI Actelion Pharmaceuticals Ltd
23721423 144 Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.EBI Actelion Pharmaceuticals Ltd.
23718281 7 Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).EBI Vanderbilt University Medical Center
23659214 138 Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.EBI Genentech
23623673 119 7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.EBI Dainippon Sumitomo Pharma. Co. Ltd
23639544 4 Synthesis of proline analogues as potent and selective cathepsin S inhibitors.EBI Hanmi Research Center
23628336 72 Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.EBI AstraZeneca
23535330 83 Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.EBI Merck Research Laboratories
23584544 12 Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.EBI Research Foundation Itsuu Laboratory
23545108 12 Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.EBI Boehringer Ingelheim (Canada) Ltd
23535326 10 Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.EBI Bioprojet-Biotech
23590342 105 ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.EBI F. Hoffmann-La Roche Ltd
23498916 4 VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.EBI ReveraGen BioPharma, Inc.
23466233 20 Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.EBI Veterans Affairs Medical Center
23350847 169 Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.EBI Hoffmann-La Roche Inc.
23570561 80 Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.EBI The Scripps Research Institute
23570514 120 Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.EBI Sirtris a GSK Company
23560650 46 Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selectives1 receptor ligands.EBI Esteve
23402880 51 The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.EBI Bristol-Myers Squibb Research& Development
23206863 7 Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK).EBI AstraZeneca
23200256 54 Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.EBI AstraZeneca
23445448 33 Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.EBI Vanderbilt University Medical Center
23394205 106 Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.EBI AstraZeneca
23380375 48 Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.EBI AMRI
23379595 55 Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.EBI Merck& Co., Inc.
23374868 76 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.EBI ChemoCentryx, Inc.
23317569 57 Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.EBI OSI Pharmaceuticals, LLC
23301703 20 Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.EBI Chinese Academy of Sciences
23294255 114 Development of new cyclic plasmin inhibitors with excellent potency and selectivity.EBI Philipps University Marburg
23260576 1 Enhanced bioactivity of silybin B methylation products.EBI University of North Carolina at Greensboro
23253441 3 The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.EBI Merck Research Laboratory
23227781 119 Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.EBI AstraZeneca
23182090 92 Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.EBI Janssen Research and Development, LLC
22545772 100 Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.EBI AstraZeneca
22094028 31 Lead optimisation of pyrazoles as novel FPR1 antagonists.EBI AstraZeneca
21955939 49 Discovery of pyrazoles as novel FPR1 antagonists.EBI AstraZeneca
21907579 22 Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.EBI AstraZeneca
21684157 68 Novel nanomolar imidazo[4,5-b]pyridines as selective nitric oxide synthase (iNOS) inhibitors: SAR and structural insights.EBI Nycomed GmbH
21669521 44 Selective non zinc binding inhibitors of MMP13.EBI AstraZeneca
19772287 67 p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.EBI GlaxoSmithKline
21574568 8 Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: alleviating drug-drug interactions through use of PubChem data and comparative molecular field analysis guided synthesis.EBI Elara Pharmaceuticals GmbH
21414782 178 Phenoxyacetic acids as PPARd partial agonists: synthesis, optimization, and in vivo efficacy.EBI GlaxoSmithKline Pharmaceuticals
16248836 154 Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.EBI F. Hoffmann-La Roche Ltd.
19632124 12 ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.EBI GlaxoSmithKline Medicines Research Centre
20627722 89 Identification of a sulfonamide series of CCR2 antagonists.EBI GlaxoSmithKline Medicines Research Centre
19664922 35 2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.EBI GlaxoSmithKline
19902954 19 Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.EBI GlaxoSmithKline Pharmaceuticals
18798607 27 Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists.EBI GlaxoSmithKline
18680280 34 Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.EBI GlaxoSmithKline
17236765 6 Identification of novel glycine sulfonamide antagonists for the EP1 receptor.EBI GlaxoSmithKline
23107482 82 Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.EBI Genentech
23079519 86 In vivo activity of an azole series of CCR2 antagonists.EBI GlaxoSmithKline Research and Development
23043539 60 Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.EBI The Institute of Cancer Research
22727372 14 Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.EBI Cardiff University
22651823 57 Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.EBI Pfizer Inc.
22607673 34 Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.EBI Vanderbilt University Medical Center
21486038 177 Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.EBI H. Lundbeck A/S
23214471 56 Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.EBI GlaxoSmithKline Research& Development
21604762 152 Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphEBI S*BIO Pte. Ltd.
23116186 68 Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).EBI AstraZeneca
23075267 85 Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.EBI Bristol-Myers Squibb Company
23072213 32 Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor.EBI Janssen-Cilag S.A.
23061660 92 Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.EBI Genentech
23061376 63 Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.EBI Roche R&D Center-China Ltd.
23009245 53 Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.EBI Sanford-Burnham Medical Research Institute
22989333 43 Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation.EBI Merck Research Laboratories
22650177 12 Design and synthesis of a novel series of bicyclic heterocycles as potent¿-secretase modulators.EBI Pharmaceutical Companies of Johnson& Johnson
22533986 181 Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.EBI ArQule Inc.
22437115 66 Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).EBI GlaxoSmithKline R&D
22409598 28 Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.EBI Pfizer Inc.
22924734 87 Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment ofEBI Pfizer Inc.
22905713 9 Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.EBI Astellas Pharma Inc.
22803959 196 Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.EBI Boehringer Ingelheim Pharmaceuticals
22784008 100 Synthesis and biological evaluation of the 1-arylpyrazole class ofs(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).EBI Esteve
22277094 59 Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17ß-HSD1.EBI Saarland University
23010262 46 Discovery of phosphoinositide 3-kinases (PI3K) p110ß isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.EBI AstraZeneca
23006603 5 Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.EBI Actelion Pharmaceuticals Ltd
22801646 49 4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy.EBI GlaxoSmithKline R&D
22793372 66 Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.EBI Vanderbilt University Medical Center
22191331 6 ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.EBI Northwestern University
23040895 37 Adamantyl carboxamides and acetamides as potent human 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.EBI University of Bath
22708876 106 Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.EBI Merck Research Laboratories
22698084 99 Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.EBI Genentech
22039836 188 Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).EBI Johnson& Johnson Pharmaceutical Research& Development
22548342 210 Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase¿ inhibitors.EBI Exelixis
22938786 86 Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.EBI Dainippon Sumitomo Pharma Co., Ltd
22884988 49 Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.EBI Amgen Inc.
22858142 121 Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.EBI AstraZeneca
22853998 164 Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.EBI Shionogi& Co., Ltd.
22832311 75 N-Aryl pyrrolidinonyl oxadiazoles as potent mGluR5 positive allosteric modulators.EBI Lundbeck Research USA, Inc.
22185670 73 Oxadiazoles in medicinal chemistry.EBI AstraZeneca
22168898 10 Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.EBI Merck Research Laboratories
22524250 12 Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.EBI Genomics Institute of the Novartis Research Foundation
22500954 99 Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).EBI GlaxoSmithKline
22732695 26 Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.EBI Bristol-Myers Squibb R&D
22727639 24 Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.EBI Vanderbilt University School of Medicine
22726929 118 Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.EBI Actelion Pharmaceuticals Ltd
22704887 12 Synthesis and evaluation of novel potent HCV NS5A inhibitors.EBI Emory University School of Medicine
22633692 51 Fused tricyclic indoles as S1P1 agonists with robust efficacy in animal models of autoimmune disease.EBI Arena Pharmaceuticals
22335519 3 Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.EBI Genentech
22749190 23 Wake-promoting agents: search for next generation modafinil: part IV.EBI Cephalon (France)
22364528 412 1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.EBI Merck Research Laboratories
22608962 59 Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.EBI AstraZeneca
22578490 35 Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.EBI Cephalon, Inc.
22542012 155 The design, synthesis, and biological evaluation of PIM kinase inhibitors.EBI Exelixis
22450133 64 Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.EBI Cephalon, Inc.
22420844 86 First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain.EBI NeurAxon Inc.
22339472 148 Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthEBI S BIO Pte. Ltd.
22239250 59 Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.EBI GlaxoSmithKline Research and Development
22617490 23 Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists.EBI Cephalon, Inc.
22607682 47 Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.EBI AstraZeneca
22607668 66 N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.EBI AstraZeneca
22560567 82 Discovery of XL413, a potent and selective CDC7 inhibitor.EBI Exelixis
22168626 32 Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.EBI Ambit Biosciences
22248262 101 Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.EBI The Beatson Institute for Cancer Research
22503453 59 The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement.EBI GlaxoSmithKline
22503248 61 Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.EBI GlaxoSmithKline
22497760 144 Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.EBI AstraZeneca
22386529 38 From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.EBI GlaxoSmithKline
22260203 73 [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.EBI Novartis Institutes for Biomedical Research
22239545 287 Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.EBI Amgen Inc.
22214363 78 Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.EBI Exelixis
22401864 61 Discovery of oxazole-based PDE4 inhibitors with picomolar potency.EBI Merck Research Laboratories
22370269 44 Discovery of P2X3 selective antagonists for the treatment of chronic pain.EBI AstraZeneca
22366657 39 A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.EBI GlaxoSmithKline R&D
22365751 45 Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.EBI Cephalon, Inc.
22148957 8 Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.EBI Merck Research Laboratories
22061639 54 Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.EBI Astrazeneca U K Ltd
21923116 40 Discovery of N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a selective inhibitor of human neuronal nitric oxide synthase (nNOS) for the treatment of pain.EBI NeurAxon Inc.
21906941 94 Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.EBI Cephalon, Inc.
21782432 62 Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity.EBI Cephalon, Inc.
21824776 31 Amine-constrained pyridazinone histamine H3 receptor antagonists.EBI Cephalon Inc.
21634396 55 Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.EBI Cephalon, Inc.
21696951 21 Indolin-2-one p38a inhibitors I: design, profiling and crystallographic binding mode.EBI Rhône-Poulenc Rorer
21608528 166 Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.EBI Merck Research Laboratories
21438541 45 Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrEBI Pfizer Inc.
21441024 74 Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.EBI Sanofi-aventis
21210664 74 Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.EBI H. Lundbeck A/S
21128593 44 Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.EBI Janssen Research and Development
21128618 60 Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.EBI University of Sussex
20724153 31 Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.EBI Korea Institute of Science and Technology
20672820 92 Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.EBI Pfizer Inc.
20614889 71 Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.EBI GlaxoSmithKline
20579874 150 BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.EBI GlaxoSmithKline R&D
20527970 29 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.EBI GlaxoSmithKline Medicines Research Centre
20491477 91 Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.EBI F. Hoffmann-La Roche Ltd.
20570147 25 Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.EBI Johnson& Johnson Pharmaceutical Research& Development
20570148 1 The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.EBI GlaxoSmithKline R&D
20568778 15 Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.EBI Novartis Institute for Tropical Diseases
20565112 55 Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.EBI Institute of Cancer Research
20420387 118 Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.EBI GlaxoSmithKline
20188553 66 Tetrahydroindolizinone NK1 antagonists.EBI Merck Research Laboratories
20000469 179 Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.EBI Boehringer Ingelheim Pharmaceuticals
19703774 56 C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II.EBI Wyeth Research
19640717 17 Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.EBI Merck Frosst Center for Therapeutic Research
19821562 34 Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.EBI Bristol-Myers Squibb Research and Development
19778024 31 Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.EBI Bristol-Myers Squibb Co
19645482 245 Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.EBI Merck Research Laboratories
19284751 26 Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable"back-up" compound for N-tert-butyl isoquine.EBI University of Liverpool
19191554 43 Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.EBI GlaxoSmithKline
18752960 48 Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.EBI Astellas Pharma. Inc.
18686943 28 Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.EBI Matrix Laboratories Limited
18662874 20 Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.EBI GlaxoSmithKline
18359226 50 Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.EBI Bristol-Myers Squibb Research and Development
18345609 57 Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.EBI The Institute of Cancer Research
18221875 59 Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.EBI Bristol-Myers Squibb Research and Development
18272363 7 Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.EBI Johnson& Johnson Pharmaceutical Research& Development
18462938 12 Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.EBI GlaxoSmithKline
18324762 20 Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.EBI Saarland University
18291645 108 Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.EBI Bristol-Myers Squibb Research and Development
18288793 24 Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215EBI Bristol-Myers Squibb Research and Development
18282707 56 Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
18061443 34 Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.EBI Merck Research Laboratories
18308567 44 Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.EBI Johnson& Johnson Pharmaceutical Research and Development
18267361 56 Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.EBI Novartis Institutes for BioMedical Research
18052318 30 4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.EBI GlaxoSmithKline Medicines REsearch Centre
17630726 32 Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.EBI Novartis Institutes for BioMedical Research
17113292 73 Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.EBI TargeGen, Inc.
16950620 36 N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.EBI Merck Sharp& Dohme Research Laboratories
17201408 91 Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.EBI Wyeth Research
16750363 101 Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.EBI Pfizer Global Research and Development
16302826 129 Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.EBI Serono Pharmaceutical Research Institute
15634016 232 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.EBI Human BioMolecular Research Institute
14761192 34 Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.EBI AstraZeneca R&D
12930139 22 Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15177483 33 SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.EBI Novartis Institutes for BioMedical Research
22341942 18 Wake-promoting agents: search for next generation modafinil: part II.EBI Cephalon, Inc.
22330635 25 Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.EBI Janssen Research& Development
22325948 52 Identification of fused bicyclic heterocycles as potent and selective 5-HT(2A) receptor antagonists for the treatment of insomnia.EBI Arena Pharmaceuticals Inc.
22318159 36 3,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors.EBI NeurAxon Inc.
22107017 47 Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H3 receptor antagonists with potent cognition enhancing activity.EBI Cephalon, Inc.
22297111 32 Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity.EBI Cephalon, Inc.
22290075 60 4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.EBI Cephalon, Inc.
22284817 82 ¿-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.EBI AstraZeneca R&D Montreal
22266039 119 Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.EBI Spanish National Cancer Research Centre (CNIO)
22266038 55 Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.EBI AstraZeneca
22264481 58 Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.EBI Arena Pharmaceuticals
22226656 75 Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT6 receptor antagonist showing activity in rat social recognition test.EBI Cephalon, Inc.
22209458 114 Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.EBI Vernalis (R&D) Ltd
22148278 132 Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinaseEBI S BIO Pte. Ltd.
22070604 150 Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor¿ (PPAR¿) modulators.EBI Merck Research Laboratories
22153941 140 Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.EBI AstraZeneca
22153662 137 Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.EBI AstraZeneca
22017539 75 Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI Boehringer Ingelheim Pharmaceuticals Inc
22172695 28 Identification of biaryl sulfone derivatives as antagonists of the histamine H3 receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).EBI Arena Pharmaceuticals
22153937 52 Novel brain penetrant benzofuropiperidine 5-HT6 receptor antagonists.EBI Cephalon, Inc.
22153342 60 Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.EBI Cephalon, Inc.
22142542 73 4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.EBI Cephalon, Inc.
22100140 10 Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.EBI University of Eastern Finland
22061640 5 Discovery of 4-aminomethylphenylacetic acids as¿-secretase modulators via a scaffold design approach.EBI Biogen Idec Inc.
22041175 74 Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.EBI Genkyotex S.A.
22019046 35 Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.EBI Sanwa Kagaku Kenkyusho Co. Ltd
22106937 83 Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.EBI Tranzyme Pharma Inc.
22059882 206 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.EBI Amira Pharmaceuticals
22030028 55 Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.EBI Merck Research Laboratories
22018461 41 Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).EBI Bristol-Myers Squibb Research and Development
22014551 33 Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.EBI Cephalon, Inc.
21978946 45 Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.EBI Takeda Pharmaceutical Company, Ltd.
21966889 61 Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinEBI Vanderbilt University Medical Center
21852130 69 Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P¿? agonists.EBI Arena Pharmaceuticals
21699209 75 Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.EBI NeurAxon Inc.
21966980 5 Novel orally active antimalarial thiazoles.EBI University of Cape Town
21958540 95 Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.EBI Amira Pharmaceuticals
21944855 30 Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity.EBI Cephalon, Inc.
21944852 79 Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.EBI AstraZeneca R&D Charnwood
21930376 92 Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.EBI Vanderbilt University Medical Center
21916510 167 Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.EBI Merck Serono S.A.
21958544 31 Indolin-2-one p38a inhibitors III: bioisosteric amide replacement.EBI Rhône-Poulenc Rorer
21924902 43 5-(2'-Pyridyl)-2-aminothiazoles: alkyl amino sulfonamides and sulfamides as potent NPY(5) antagonists.EBI Lundbeck Research USA, Inc.
21942426 113 Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.EBI Merck& Co.
21936542 143 Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.EBI Novartis Institute for BioMedical Research
21917454 159 Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.EBI Johnson& Johnson Pharmaceutical Research and Development
21885275 65 Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.EBI Pfizer Inc.
21873051 31 Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
21866910 66 N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT6R) antagonists with unique structural features.EBI Abbott Healthcare Products B.V.
21838322 37 Discovery of a brain-penetrant S1P3-sparing direct agonist of the S1P¿? and S1P5 receptors efficacious at low oral dose.EBI GlaxoSmithKline
21782428 61 Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.EBI Lundbeck Research USA, Inc.
21899292 76 Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.EBI AstraZeneca
21838328 35 Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).EBI Cardiff University
21786805 130 Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.EBI Vitae Pharmaceuticals
21634430 218 Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.EBI S*BIO Pte Ltd.
21859094 61 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.EBI Cephalon, Inc.
21823597 373 Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.EBI Green Cross Corporation
21803580 115 Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.EBI Merck Research Laboratories Rome
21798739 6 Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPAR¿ partial agonist.EBI GlaxoSmithKline
21798738 44 Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).EBI Biogen Idec Inc.
21783360 52 Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.EBI Bioprojet-Biotech
21591694 34 Development ofß-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics.EBI University of Colorado at Boulder
21865048 29 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.EBI Dainippon Sumitomo Pharma Co. Ltd
21550808 25 1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors.EBI GlaxoSmithKline Medicines Research Centre
21515056 61 Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.EBI AstraZeneca Research and Development
21739935 62 Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.EBI Sunovion Pharmaceuticals
21737263 63 Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.EBI Merck Research Laboratories Rome
21705217 60 Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38a MAP kinase inhibitors.EBI Bristol-Myers Squibb
20931971 155 Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOEBI Kalypsys, Inc
20634071 41 Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X(7) antagonists.EBI GlaxoSmithKline
21644570 25 Imidazolopiperazines: hit to lead optimization of new antimalarial agents.EBI Genomics Institute of the Novartis Research Foundation
20933411 69 Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.EBI Merck Frosst Centre for Therapeutic Research
19447034 76 Discovery of selective PDE4B inhibitors.EBI Asahi Kasei Pharma Corporation
21507633 77 The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.EBI Genzyme Corp.
21592791 61 Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.EBI AstraZeneca R&D Charnwood
21565499 32 Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.EBI Pfizer Inc.
21550240 9 From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.EBI Boehringer Ingelheim (Canada) Ltd
21536438 74 Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.EBI Merck Research Laboratories
21515053 58 New indole amide derivatives as potent CRTH2 receptor antagonists.EBI Merck Frosst
21514824 91 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.EBI Merck Research Laboratories
21444206 53 Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.EBI Arena Pharmaceuticals
21195614 56 Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.EBI Pfizer Inc.
21428449 27 Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.EBI Cardiff University
21413799 63 Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.EBI Hoffmann-La Roche Inc.
21384875 67 Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.EBI Saarland University
21381763 52 The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.EBI GlaxoSmithKline Medicines Research Centre
21375347 5 Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.EBI Northwestern University
21375264 77 Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitorsEBI Roche Palo Alto LLC
21388809 76 Discovery of benzothiazole-based adenosine A2B receptor antagonists with improved A2A selectivity.EBI Roche Research Center
21376585 120 Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.EBI Euroscreen SA
21354795 95 1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.EBI Boehringer Ingelheim Pharmaceuticals
21334894 218 Substituted phenyl triazoles as selective inhibitors of 11 β-Hydroxysteroid Dehydrogenase Type 1.EBI Merck& Co
21411321 28 Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.EBI Merck Research Laboratories
21324691 24 N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.EBI Pfizer Inc.
21324688 36 1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.EBI Pfizer Inc.
21310612 99 Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.EBI Sunovion Pharmaceuticals Inc.
21256005 51 Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.EBI GlaxoSmithKline
21269824 112 Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.EBI F. Hoffmann-La Roche Ltd
21256008 44 Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.EBI Ono Pharmaceutical Co., Ltd
21251824 24 Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.EBI OSI Pharmaceuticals, Inc.
21211969 42 Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.EBI USA.
21189020 54 New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17ß-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.EBI Saarland University
19289530 25 Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.EBI Genzyme Corporation
21095126 60 Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.EBI Sunovion Pharmaceuticals Inc
21093273 154 Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.EBI Sepracor Inc.
21074994 46 Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.EBI Cephalon, Inc
21147532 82 Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.EBI Merck Research Laboratories
21134748 59 Stereospecific synthesis and structure-activity relationships of unsymmetrical 4,4-diphenylbut-3-enyl derivatives of nipecotic acid as GAT-1 inhibitors.EBI GlaxoSmithKline
21106375 198 Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.EBI Merck Frosst Centre for Therapeutic Research
21195616 26 A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain.EBI Merck Research Laboratories
21185722 74 Azaindoles as potent CRTH2 receptor antagonists.EBI Merck Frosst Centre for Therapeutic Research
19029327 7 In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.EBI Pfizer Inc.
19029318 15 Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.EBI Indiana University
21106456 35 Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.EBI Merck Research Laboratories
20974532 57 Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.EBI F. Hoffmann-La Roche Ltd
21074434 4 Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.EBI Merck Research Laboratories
21055936 14 Synthesis and pharmacological characterization of 5-phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones: a new class of Neuropeptide S antagonists.EBI GlaxoSmithKline Medicines Research Centre
21036042 7 Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK.EBI Pfizer Inc.
21035336 42 5-amino-pyrazoles as potent and selective p38a inhibitors.EBI Bristol-Myers Squibb Research and Development
20961756 61 5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.EBI AMRI
20952195 62 Tetrahydrocarboline analogs as MCH-1 antagonists.EBI AMRI
20951036 47 Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.EBI AMRI
20942472 88 Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.EBI GlaxoSmithKline
20942471 79 First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.EBI Genkyotex, S.A.
20801551 34 Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.EBI Daiichi Sankyo Co., Ltd.
21033679 6 Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.EBI Johnson& Johnson Pharmaceutical Research and Development
20933413 74 2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.EBI GlaxoSmithKline Medicines Research Centre
20933409 50 Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.EBI Green Cross Corporation
20926294 65 3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.EBI GlaxoSmithKline Pharmaceuticals
20888225 17 Discovery of a vorapaxar analog with increased aqueous solubility.EBI Merck Research Laboratories
20864344 110 Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.EBI Vitae Pharmaceuticals
20850301 68 Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.EBI AstraZeneca
20843687 60 Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.EBI Merck Research Laboratories
20839775 60 Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.EBI GlaxoSmithKline Medicines Research Centre
20832301 6 Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations.EBI Sun Yat-Sen University
20801030 106 Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.EBI F Hoffmann-La Roche Ltd
20729082 59 Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.EBI Merck Research Laboratories
20804198 29 Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38a MAP kinase inhibitor for the treatment of inflammatory diseases.EBI Bristol-Myers Squibb Research and Development
20590088 124 Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).EBI GlaxoSmithKline
20709552 36 Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.EBI Merck Research Laboratories
20709545 31 Substituted biaryl pyrazoles as sodium channel blockers.EBI Merck Research Laboratories
20685118 97 The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.EBI Merck Research Laboratories
20673729 60 Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.EBI Green Cross Corporation
19933795 12 SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.EBI Scynexis, Inc.
20630754 33 Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.EBI GlaxoSmithKline
20598880 48 Discovery of novel sphingosine kinase-1 inhibitors. Part 2.EBI Genzyme Corporation
20598534 105 Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.EBI Bristol-Myers Squibb
20594842 90 Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.EBI GlaxoSmithKline
20573506 39 A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.EBI GlaxoSmithKline Medicines Research Centre
20566292 6 5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.EBI Amira Pharmaceuticals
20472432 29 Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.EBI Boehringer Ingelheim Pharmaceuticals
20465278 27 Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).EBI Amgen Inc.
20452209 64 Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.EBI Merck Research Laboratories
20405922 53 Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).EBI Bristol-Myers Squibb Research and Development
20380377 70 Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.EBI Roche Research Center
20423086 93 Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.EBI Merck Research Laboratories
20223663 100 2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.EBI Wyeth Research
20223662 174 Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.EBI Yangji Chemicals
20218621 131 Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).EBI Bristol-Myers Squibb
20218619 44 Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.EBI Amgen Inc.
20189807 32 Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.EBI Sanofi-aventis
20096577 42 Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.EBI Merck Research Laboratories
20185309 15 Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.EBI Boehringer Ingelheim (Canada) Ltd
20184326 40 Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.EBI Merck Research Laboratories
20149649 133 Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.EBI Green Cross Corporation
20138761 30 Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.EBI Amgen Inc.
19891474 131 1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.EBI GlaxoSmithKline Medicines Research Centre
19846298 119 Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).EBI GlaxoSmithKline R&D
19804969 109 The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.EBI GlaxoSmithKline
19682899 211 Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.EBI Merck Research Laboratories
19647430 104 N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.EBI Pfizer Global Research and Development
19515564 3 Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase.EBI GlaxoSmithKline
20022752 94 Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.EBI Bristol-Myers Squibb Co
20170186 49 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.EBI GlaxoSmithKline Medicine Research Centre
20151677 67 Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).EBI Institute of Cancer Research
20089400 27 Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.EBI Johnson& Johnson Pharmaceutical Research and Development
20064717 64 Spirocyclic ureas: orally bioavailable 11beta-HSD1 inhibitors identified by computer-aided drug design.EBI Vitae Pharmaceuticals
20005710 70 Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.EBI Merck Research Laboratories
20005102 34 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.EBI GlaxoSmithKline
19969453 73 Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.EBI Boehringer Ingelheim Pharmaceuticals
19962893 3 The comparative antimalarial properties of weak base and neutral synthetic ozonides.EBI University of Nebraska Medical Center
19945870 10 Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.EBI Boehringer Ingelheim (Canada) Ltd
19926282 136 Improving the developability profile of pyrrolidine progesterone receptor partial agonists.EBI GlaxoSmithKline Pharmaceuticals
19914828 37 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.EBI Amira Pharmaceuticals
19914064 9 Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines.EBI Institute Infectious Diseases Initiative
19957930 126 Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent thatEBI deCODE Chemistry, Inc.
19883100 3 Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.EBI Merck Research Laboratory
19769332 49 Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activityEBI Bristol-Myers Squibb Research and Development
19743867 51 Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.EBI GlaxoSmithKline
19716296 32 GDC-0449-a potent inhibitor of the hedgehog pathway.EBI Genentech
19699641 145 Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.EBI Institute Infectious Diseases Initiative
19683918 36 Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.EBI Pfizer Global Research and Development
19888755 43 Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.EBI Wyeth Research
19810674 93 Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B EBI Universita degli Studi di Bari
19783143 65 Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.EBI Novartis Institutes for BioMedical Research
19524437 31 Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.EBI Hoffmann-La Roche Ltd
19746975 67 Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.EBI Boehringer Ingelheim Pharmaceuticals
19739647 52 5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).EBI Amira Pharmaceuticals
19616432 176 Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.EBI Pfizer Global Research and Development
19608418 95 Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.EBI Amira Pharmaceuticals
19592244 61 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.EBI Novartis Institutes of Biomedical Research
19574047 42 Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.EBI Amgen Inc
19541481 57 Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.EBI Bristol-Myers Squibb Company
19520574 49 Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.EBI Tsukuba Research Institute
19719241 55 Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.EBI Wyeth Research
19537798 22 Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.EBI Tsukuba Research Institute
19530681 79 Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.EBI Merck Research Laboratories
19481450 121 Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.EBI Schering-Plough Research Institute
19209845 12 Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.EBI Pfizer Global Research and Development
19222165 36 Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.EBI University of Liverpool
19481932 164 Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.EBI Merck Research Laboratories
19467868 131 Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).EBI GlaxoSmithKline R&D
19441846 35 Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.EBI IRBM/Merck Research Laboratories
19419866 24 Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).EBI Bristol-Myers Squibb Pharmaceutical Research and Development
19419141 23 Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.EBI Abbott Laboratories
19364658 113 Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).EBI Wyeth Research
19354254 24 Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.EBI Merck Research Laboratories
19339177 127 The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.EBI Schering-Plough Research Institute
19332369 43 Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.EBI GlaxoSmithKline
19323562 14 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.EBI Abbott Laboratories
19320488 171 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.EBI Merck Research Laboratories
19309152 81 Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.EBI Merck Research Laboratories
19275964 64 (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.EBI Pfizer Global Research & Development
19256507 5 Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.EBI Celgene Corporation
19231183 44 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.EBI AstraZeneca
19140664 82 N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.EBI Neurocrine Biosciences
19119007 34 Novel imidazole-based histamine H3 antagonists.EBI Johnson & Johnson Pharmaceutical Research & Development
19097792 24 Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.EBI AstraZeneca R&D Boston
19095443 66 Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.EBI GlaxoSmithKline
19095442 70 Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.EBI GlaxoSmithKline
19053768 64 Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.EBI Novartis Institutes for BioMedical Research
19053752 25 Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues.EBI Washington State University
19049427 98 In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.EBI Saarland University
19036582 45 Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.EBI GlaxoSmithKline
19019676 94 Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.EBI Medicines Research Centre
19014886 83 Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.EBI GlaxoSmithKline
19010671 28 Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.EBI GlaxoSmithKline PLC
19006669 82 The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.EBI GlaxoSmithKline
18954983 12 Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.EBI Kalypsys, Inc.
18952417 50 Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.EBI IRBM-Merck Research Laboratories Rome
18835163 41 Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.EBI Merck Frosst Center for Therapeutic Research
18823779 27 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).EBI Johnson & Johnson Pharmaceutical Research and Development
18805008 133 Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.EBI F. Hoffmann-La Roche Ltd.
18763754 57 Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.EBI Saarland University
18752953 111 Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.EBI F. Hoffmann-La Roche Ltd
18701276 97 Highly functionalized 7-azaindoles as selective PPAR gamma modulators.EBI Merck Research Laboratories
18672861 91 Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.EBI Saarland University
18665579 21 Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficEBI Bristol-Myers Squibb Research & Development
18632268 8 Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.EBI Roche Palo Alto LLC
18621528 133 Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.EBI Pfizer Global Research and Development
18614366 97 Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.EBI GlaxoSmithKline R&D
18598020 75 Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.EBI Tsukuba Research Institute
18539454 47 Imidazopyridines as VLA-4 integrin antagonists.EBI UCB
18539028 81 Discovery of potent, orally active benzimidazole glucagon receptor antagonists.EBI Merck Research Laboratories
18477506 7 Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.EBI Merck Research Laboratories
18255300 13 Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.EBI Washington State University
18249473 97 Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.EBI Vrije Universiteit
18211009 2 High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods.EBI Washington State University
18207397 18 Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.EBI Merck Frosst Center for Therapeutic Research
17994683 55 Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor.EBI Neurocrine Biosciences, Inc.
17988109 11 Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.EBI Pfizer Global Research and Development
17933533 36 Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.EBI Institute of Cancer Research
17918824 39 Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.EBI Neurocrine Biosciences, Inc.
17915853 14 CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.EBI AstraZeneca R&D Mölndal
17869105 42 Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.EBI Johnson & Johnson Pharmaceutical Research and Development
17855089 25 Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17761416 53 The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.EBI Merck Research Laboratories
17723300 55 Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.EBI Merck Research Laboratories
17722903 57 Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.EBI AstraZeneca Discovery
17705360 76 Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.EBI Wyeth Research
17629698 36 Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.EBI GlaxoSmithKline
17531480 51 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.EBI Novartis Institutes of Biomedical Research
17524641 69 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.EBI GlaxoSmithKline
17477516 115 Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.EBI GlaxoSmithKline
17428043 5 Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.EBI P. Angeletti S.p.A. (Merck Research Laboratories
17418568 50 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.EBI F. Hoffmann-La Roche Ltd
17400452 42 PDE-10A inhibitors as insulin secretagogues.EBI Bayer Pharmaceuticals Corporation
17399990 45 In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).EBI Université Laval
17398093 72 Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17352462 90 Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).EBI Via Zambeletti 25
17276061 6 In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity.EBI Pfizer Inc.
17249648 64 Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.EBI Merck Research Laboratories
17084082 7 The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.EBI GSK
17084080 15 Studies towards the identification of a new generation of atypical antipsychotic agents.EBI UK. Vinc
17055721 80 Discovery of potent and selective PKC-theta inhibitors.EBI Boehringer Ingelheim Pharmaceuticals
17027263 42 Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.EBI Merck Research Laboratories
16971122 4 Inhibitors of unactivated p38 MAP kinase.EBI Johnson and Johnson Pharmaceutical Research and Development
16950617 50 N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.EBI Merck Sharp & Dohme Research Laboratories
16843659 5 Identification of novel pyrazole acid antagonists for the EP1 receptor.EBI GlaxoSmithKline
16821776 13 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.EBI Cardiovascular and Urogenital Centre of Excellence for Drug Discovery
16806913 6 N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.EBI GlaxoSmithKline
16753296 25 Discovery of potent CRTh2 (DP2) receptor antagonists.EBI AstraZeneca R&D Charnwood
16722655 28 Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.EBI Pfizer Global Research & Development
16697196 1 Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists.EBI GlaxoSmithKline
16686533 89 Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.EBI Boehringer Ingelheim Pharmaceuticals
16647256 16 Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.EBI Arpida A/S
16631366 26 Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.EBI AstraZeneca
16504501 54 3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.EBI OSI Pharmaceuticals, Inc.
16503138 15 Discovery of novel biaryl heterocyclic EP1 receptor antagonists.EBI GlaxoSmithKline
16495056 23 Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.EBI Universite Paris 5 René Descartes
16451063 139 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.EBI GlaxoSmithKline
16134939 67 Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.EBI Chiesi Farmaceutici S.p.A.
16134929 22 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.EBI Bristol-Myers Squibb Co
16107158 60 Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.EBI Boehringer Ingelheim (Canada) Ltd.
16061379 32 Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15943473 136 Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15863293 30 Selective PPARgamma modulators with improved pharmacological profiles.EBI Merck Research Laboratories
15837312 66 Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.EBI Celltech R&D Ltd
15745819 64 Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).EBI OSI Pharmaceuticals, Inc.
15615526 16 Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors.EBI Washington State University
15546728 15 Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.EBI Aventis Pharmaceuticals
15177482 86 Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.EBI Novartis Institutes for BioMedical Research
15139756 221 Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.EBI Actelion Pharmaceuticals Ltd.
15013017 49 Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase.EBI Pharmaceutical Research Institute
14698201 47 New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.EBI CV Therapeutics
14698153 46 Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.EBI Taisho Pharmaceutical Co., Ltd
14640550 132 Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.EBI Taisho Pharmaceutical Co, Ltd
14584934 15 Identification of a potent and selective 5-HT(6) antagonist: one-step synthesis of (E)-3-(benzenesulfonyl)-2- (methylsulfanyl)pyrido[1,2-a]pyrimidin-4-ylidenamine from 2-(benzenesulfonyl)-3,3-bis(methylsulfanyl)acrylonitrile.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12643910 5 Identification of a novel series of selective 5-HT7 receptor antagonists.EBI GlaxoSmithKline
12593666 30 Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.EBI Senju Pharmaceutical Co.
12372506 41 Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.EBI Johnson and Johnson Pharmaceutical Research and Development
12182870 53 The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.EBI GlaxoSmithKline
11714595 43 Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.EBI Taisho Pharmaceutical Co., Ltd.
11606127 96 Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.EBI Université Paris V
10956186 43 A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.EBI Washington State University
10737744 146 Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.EBI SmithKline Beecham Pharmaceuticals
9925723 10 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.EBI SmithKline Beecham Pharmaceuticals
9357513 15 6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.EBI SmithKline Beecham Pharmaceuticals
24047900 19 Complexes of Trypanosoma cruzi sterol 14a-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.BDB Vanderbilt University
18620382 41 Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.BDB GSK
17948978 29 Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.BDB Wyeth Research
18311908 42 Characterization of Type II Ligands in CYP2C9 and CYP3A4.BDB AstraZeneca